AUTHOR=Wang Haoqi , Gao Shan , Bai Zihao , Wang Lijia , Geng Cuizhi 

TITLE=Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response

JOURNAL=Frontiers in Oncology

VOLUME=Volume 15 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1673810

DOI=10.3389/fonc.2025.1673810

ISSN=2234-943X

ABSTRACT=BackgroundThe development of a robust and clinically applicable predictive model for pathological complete response (pCR) following neoadjuvant therapy (NAT) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is of critical importance.MethodsIn this retrospective study, 393 female patients with stage II–III BC who received NAT followed by surgery between May 2021 and December 2023 were included. Clinicopathological data, apparent diffusion coefficient (ADC) values from breast MRI, and pathological remission after NAT were collected. The change rate of ADC values after two cycles of NAT (ΔADC0-2%) was calculated. The efficacy of NAT regimens containing trastuzumab plus pertuzumab (HP) and trastuzumab plus pyrotinib (HPy) was compared. A nomogram predicting pCR was constructed, and its performance was evaluated. The model was internally validated using the bootstrap resampling method.ResultsThe rate of total pathological complete response (tpCR) in the overall population was 68%. There was no statistically significant difference in tpCR between the HP and HPy groups (P > 0.05). Hormone receptor (HR) negativity, HER2 3+, high Ki-67 index, moderate-highly (M-H) infiltrated tumor-infiltrating lymphocytes (TILs), and ΔADC0-2% > 36.2% were independently associated with tpCR (P < 0.05). The nomogram integrating these variables exhibited good discrimination (AUC, 0.75) and calibration ability (P = 0.925), as well as valuable clinical applicability.ConclusionBoth HP and HPy combined with chemotherapy can be considered as optional NAT regimens for HER2-positive BC. The nomogram incorporating common clinical indicators provides a basis for clinicians to predict NAT efficacy at an earlier stage.